Drug intelligence / Profile preview

ImunoVip

Development stage: Unknown
Lead developer: Royal Medicalink Pharma
Administration: Oral

Overview

ImunoVip is an Indonesian herbal supplement developed and manufactured by PT Royal Medicalink Pharmalab. It is formulated as an immunomodulator to support and maintain the body's immune system. The product typically contains a combination of natural extracts, including *Phyllanthus niruri* (meniran), *Curcuma xanthorrhiza* (temulawak), and *Channa striata* (snakehead fish) extract. *Phyllanthus niruri* is known for its immunomodulatory properties, while *Channa striata* provides high levels of albumin and amino acids to aid in tissue repair and nutritional support. It is marketed in Indonesia as both an over-the-counter (OTC) and ethical product, registered with the Indonesian Food and Drug Authority (BPOM) under the traditional medicine category.

Brand names: ImunoVip

Beyond the preview

Go deeper on ImunoVip.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImunoVip.

Explore the full profile